Therapeutics News and Research

RSS

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Anchor Therapeutics today announced the publication of new research in the Proceedings of the National Academy of Sciences USA. The paper describes the identification and characterization of a pepducin-based allosteric agonist that targets CXCR4, a chemokine G protein-coupled receptor found on hematopoietic stem cells and other bone marrow-derived cells.

9 Dec 2010

NIH to create new translational science center

National Institutes of Health (NIH) Director Francis Collins on Tuesday announced the agency is moving forward on plans to create a new research center focused on translational science, after NIH's advisory board voted to create the new center, Science's "Science Insider" blog reports (Kaiser, 12/7).

9 Dec 2010

UBC's new formulation of Amphotericin B for Visceral Leishmaniasis remains stable in tropical climates

A new formulation of Amphotericin B (AmB) developed by University of British Columbia researchers has been shown to be stable in tropical climates and effective in treating Visceral Leishmaniasis (VL) in mouse models.

8 Dec 2010

North Tees and Hartlepool NHS Foundation Trust pioneer novel technique for breast reconstruction

Surgeons at North Tees and Hartlepool NHS Foundation Trust are pioneering a novel technique for breast reconstruction that has the potential to make a huge difference to the lives of women affected by breast cancer.

8 Dec 2010

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

Investigators at Southern Methodist University and The University of Texas at Dallas have discovered a family of small molecules that shows promise in protecting brain cells against nerve-degenerative diseases such as Parkinson's, Alzheimer's and Huntington's, which afflict millions.

8 Dec 2010

IEEE members are transforming the future of medicine and healthcare

Members of IEEE, the world's largest technical professional association, are advancing the application of engineering sciences and technology with medicine and biology to make healthcare personal again.

8 Dec 2010

New technique may help develop novel treatments for brain diseases

Scientists have created a way to isolate neural stem cells - cells that give rise to all the cell types of the brain - from human brain tissue with unprecedented precision, an important step toward developing new treatments for conditions of the nervous system, like Parkinson's and Huntington's diseases and spinal cord injury.

8 Dec 2010

Children's Hospital LA investigators elected into the Society for Pediatric Research

Three investigators from The Saban Research Institute of Children's Hospital Los Angeles have been elected into the prestigious Society for Pediatric Research. Their election to this Society represents peer recognition of their research achievements in pediatrics.

8 Dec 2010

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

Cephalon, Inc. and Mesoblast Limited, today announced they have entered into a strategic alliance to develop and commercialize novel adult Mesenchymal Precursor Stem Cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems.

8 Dec 2010

BioMimetic Therapeutics to assess safety, clinical utility of Augment Rotator Cuff Graft

BioMimetic Therapeutics, Inc. today announced it initiated enrollment in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears. The randomized, controlled pilot trial is expected to include enrollment of up to 30 patients.

8 Dec 2010

FDA Advisory Committee votes in favor of Orexigen's Contrave for treatment of obesity

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 7 that the available data adequately demonstrate that the potential benefits of Contrave® (naltrexone sustained release (SR)/bupropion SR) outweigh the potential risks when used long-term in a population of overweight and obese individuals and support approval.

8 Dec 2010

Researchers synthesize wound-healing peptides

Newly-created bioactive peptides promote wound healing through the growth of new blood vessels and epithelial tissue, such as skin. These wound-healing peptides, synthesized by researchers at the Tufts Center for Innovations in Wound Healing Research, increased angiogenesis in vitro by 200 percent.

8 Dec 2010

Swissmedic authorizes Phase I/II clinical trial of human neural stem cells for chronic spinal cord injury

A therapy developed by Aileen Anderson and Brian Cummings of UC Irvine's Sue and Bill Gross Stem Cell Research Center in collaboration with researchers at StemCells Inc. will be the basis of the world's first clinical trial using human neural stem cells to treat spinal cord injury.

8 Dec 2010

NIH awards Scripps Research $2.35M to study new treatment for obesity

The Scripps Research Institute has been awarded a $2.35 million grant from the National Institutes of Health to study a new way of treating obesity as part of a national consortium with the Dana-Farber Cancer Institute.

8 Dec 2010

Contrave, new weight loss pill gets FDA panel nod

A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics’ weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave’s approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel’s recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.

7 Dec 2010

Roche completes enrollment in Herceptin SC Phase 3 trial for HER2-positive breast cancer

Halozyme Therapeutics, Inc. today announced that Roche has completed patient enrollment for the pivotal Phase 3 study of Herceptin SC (trastuzumab subcutaneous), a subcutaneous formulation that uses Halozyme's Enhanze™ technology (rHuPH20, recombinant human hyaluronidase).

7 Dec 2010

Idis to manage ViroPharma's named patient program

ViroPharma Incorporated and Idis, the global leader in developing long-term strategic solutions to therapeutic access, today announced that the two companies have partnered to facilitate access to certain ViroPharma products through a named patient program (NPP). ViroPharma's NPP, developed and managed by Idis, will allow international healthcare professionals to prescribe certain products to individual patients until the time that approval is sought in local countries.

7 Dec 2010

Cylene Pharmaceuticals to present data on CK2 inhibitor at ASH Annual Meeting

Cylene Pharmaceuticals, Inc. has been selected to present data describing the activity of their first-in-class CK2 inhibitor at the 52nd Annual Meeting of the American Society of Hematology, to be held on December 4-7 in Orlando, FL, the company announced today. Kenna Anderes, VP Cancer Biology at Cylene, will discuss research on targeting CK2, a protein kinase that is essential for the progression of multiple myeloma but that has not been previously exploited as an anticancer target.

7 Dec 2010

Rexahn Pharmaceuticals announces US patent for cognition enhancement

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,842,683 entitled, "Neurotherapeutic Compositions and Methods."

7 Dec 2010

Ascenta, LLS enter agreement to develop AT-406 IAP small molecule inhibitor for acute myeloid leukemia

Ascenta Therapeutics, Inc. and The Leukemia & Lymphoma Society (LLS) today entered into an agreement whereby the LLS will support clinical development of Ascenta's oral small molecule inhibitor of IAPs (inhibitor of apoptosis proteins), AT-406, for patients with acute myeloid leukemia (AML).

7 Dec 2010

Therapeutics News and Research

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

NIH to create new translational science center

UBC's new formulation of Amphotericin B for Visceral Leishmaniasis remains stable in tropical climates

North Tees and Hartlepool NHS Foundation Trust pioneer novel technique for breast reconstruction

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

IEEE members are transforming the future of medicine and healthcare

New technique may help develop novel treatments for brain diseases

Children's Hospital LA investigators elected into the Society for Pediatric Research

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

BioMimetic Therapeutics to assess safety, clinical utility of Augment Rotator Cuff Graft

FDA Advisory Committee votes in favor of Orexigen's Contrave for treatment of obesity

Researchers synthesize wound-healing peptides

Swissmedic authorizes Phase I/II clinical trial of human neural stem cells for chronic spinal cord injury

NIH awards Scripps Research $2.35M to study new treatment for obesity

Contrave, new weight loss pill gets FDA panel nod

Roche completes enrollment in Herceptin SC Phase 3 trial for HER2-positive breast cancer

Idis to manage ViroPharma's named patient program

Cylene Pharmaceuticals to present data on CK2 inhibitor at ASH Annual Meeting

Rexahn Pharmaceuticals announces US patent for cognition enhancement

Ascenta, LLS enter agreement to develop AT-406 IAP small molecule inhibitor for acute myeloid leukemia

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News